~~IN THE~~ CLAIMS:

1. A liquid pharmaceutical formulation comprising a therapeutically effective amount of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-l ,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide (ST-246) and cyclodextrin, and further comprising one or more pharmaceutically acceptable ingredients.

2. The liquid pharmaceutical formulation of claim 1, wherein said pharmaceutically acceptable ingredients are selected from the group consisting of carrier, excipient, diluent, additive, filler, lubricant and binder.

3. The liquid pharmaceutical formulation of claim 1 or 2, wherein said cyclodextrin is hydroxypropyl-β-cyclodextrin.

4. The liquid pharmaceutical formulation of any one of claims 1 to 3, wherein said cyclodextrin is hydroxypropyl-β-cyclodextrin and is present in amounts from ~~about~~ 20% to ~~about~~ 40% by weight.

5. The liquid pharmaceutical formulation of any one of claims 1 to 4, wherein said cyclodextrin is hydroxypropyl-β-cyclodextrin and has a degree of substitution of between 4.0 to 8.0.

~~5~~6. The liquid pharmaceutical formulation of claim 1 or 2, wherein said cyclodextrin is sufobutyl-ether-β-cylodextrin.

~~6~~7. The liquid pharmaceutical formulation of any one of claims 1 to 6, wherein the liquid pharmaceutical formulation has~~ving~~ a pH between ~~about~~ 3 and 10.

~~7. The liquid pharmaceutical formulation of claim 3, wherein said hydroxypropyl-β-cyclodextrin has a degree of substitution of between about 4.0 to about 8.0.~~

8. A liquid pharmaceutical formulation according to any one of claims 1 to 7 for use in medicine.

~~8~~9. ~~A method of~~Use of a liquid pharmaceutical formulation according to any one of claims 1 to 7 in the manufacture of a medicament for the treatment of ~~treating~~ orthopoxvirus infections and/or eczema vaccinatum ~~comprising administering to a subject in need thereof a liquid pharmaceutical formulation according to claim 1~~.

~~9~~10. The ~~method~~use of claim ~~8~~9, wherein ~~said liquid formulation is administered by~~the medicament is for parenteral administration, oral administration, topical administration, or intravenous administration.

~~10. The method of claim 8, wherein said liquid formulation is administered by oral administration.~~

~~11. The method of claim 8, wherein said liquid formulation is administered by topical administration.~~

~~12. The method of claim 8, wherein said liquid formulation is administered by intravenous administration.~~

~~13~~11. The ~~method~~use of claim ~~12~~9, wherein the medicament is for intravenous administration, and wherein ~~about~~ 50 to ~~about~~ 500 mg of ST-246 is infused per single session of intravenous administration, 200 to 400 mg of ST-246 is infused per single session of intravenous administration, 300 mg of ST-246 is infused per single session of intravenous administration, said treatment is carried out for a period ranging from 7 to 30 days, said treatment is carried out for a period ranging from 7 to 15 days, the duration of each session of intravenous administration is from 2 to 24 hours, said treatment is carried out continuously over the course of treatment at a dosage of 50 to 500 mg of ST-246 per day, or said intravenous administration is carried out during two sessions per day in which the duration of each session is from 2 to 12 hours.

~~14. The method of claim 12, wherein about 200 to about 400 mg of ST-246 is infused per single session of intravenous administration.~~

~~15. The method of claim 12, wherein about 300 mg of ST-246 is infused per single session of intravenous administration.~~

~~16. The method of claim 12, wherein said treatment is carried out for a period ranging from about 7 to about 30 days.~~

~~17. The method of claim 12, wherein said treatment is carried out for a period ranging from about 7 to about 15 days.~~

~~18. The method of claim 12, wherein the duration of each session of intravenous administration is from about 2 to about 24 hours.~~

~~19. The method of claim 12, wherein said treatment is carried out continuously over the course of treatment at a dosage of about 50 to about 500 mg of ST-246 per day.~~

~~20. The method of claim 12, wherein said intravenous administration is carried out during two sessions per day.~~

~~21. The method of claim 20, wherein the duration of each session is from about 2 to about 12 hours.~~

~~22~~12. A process of making liquid formulation according to any one of claims 1 to 7 comprising ~~the steps of~~:
a) mixing ST-246 with cyclodextrin in a pharmaceutically acceptable liquid carrier~~; and b) optionally filtering the mixture of step a)~~.

13. The process according to claim 12 comprising b) filtering the mixture of step a).

~~23~~14. The process of claim ~~22~~12 or 13, wherein said ST-246 is selected from a group consisting of ST-246 polymorph Form I, ST-246 polymorph Form II, ST-246 polymorph Form III, ST-246 polymorph Form IV, ST-246 polymorph Form V and ST-246 polymorph Form VI.

~~24. The process of claim 22, wherein said cyclodextrin is hydroxypropyl β-cyclodextrin.~~

~~25. The process of claim 22, wherein said hydroxypropyl-β-cyclodextrin is present in amounts from about 20% to about 40% by weight.~~

~~26~~15. The process of any one of claims ~~22~~12 to 14, wherein said liquid formulation is adjusted to a pH between ~~about~~ 3 and 10, the mixture of step (a) is brought to solubility equilibrium at a temperature of about 25°C, the mixture of step (a) is brought to solubility equilibrium at a temperature of about 37°C, or said ST-246 is mixed with pharmaceutically acceptable carrier for about 72 hours.

~~27. The process of claim 24, wherein said hydroxypropyl-β-cyclodextrin has a degree of substitution between about 4.0 to about 8.0.~~

~~28. The process of claim 22, wherein the mixture of step (a) is brought to solubility equilibrium at a temperature of about 25°C.~~

~~29. The process of claim 22, wherein the mixture of step (a) is brought to solubility equilibrium at a temperature of about 37°C.~~

~~30. The process of claim 22, wherein said ST-246 is mixed with pharmaceutically acceptable carrier for about 72 hours.~~

~~31~~16. A unit dosage liquid formulation comprising:
a) 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-l ,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide (ST-246) content ranging from ~~about~~ 2 mg/ml to ~~about~~ 20 mg/ml; and
b) hydroxypropyl-β-cyclodextrin content ranging from ~~about~~ 12.5 mg/ml to ~~about~~ 40 mg/ml.

~~32~~17. The unit dosage liquid formulation of claim ~~31~~16 further comprising one or more pharmaceutically acceptable ingredients selected from the group consisting of: mannitol, trehalose dehydrate, lactose monohydrate, and purified water or selected from the group consisting of: polyethylene glycol 400, polysorbate 80, polyethylene glycol 300, and purified water.

~~33~~18. The unit dosage liquid formulation of claim ~~31~~16 or 17 having a pH range from ~~about~~ 3.0 to ~~about~~ 10.0, or having a total volume of 100 ml.

~~34. The unit dosage liquid formulation of claim 31 having a total volume of about 100 ml.~~

~~35. A unit dosage liquid formulation comprising:~~
~~a) ST-246 ranging from about 2 mg/ml to about 20 mg/ml; and~~
~~b) hydroxypropyl-β-cyclodextrin content ranging from about 12.5 mg/ml to about 40 mg/ml.~~

~~36. The unit dosage liquid formulation of claim 35 further comprising one or more pharmaceutically acceptable ingredients selected from the group consisting of: polyethylene glycol 400, polysorbate 80, polyethylene glycol 300, and purified water~~

~~37. The unit dosage liquid formulation of claim 35 having a total volume of about 100 ml.~~

~~38. The unit dosage liquid formulation of claim 35 having a pH range from about 3.0 to about 10.0.~~

~~39~~19. A process for preparing a water-soluble solid 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-l ,3-dioxo-4,6ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide (ST-246) pharmaceutical formulation comprising:
a) mixing ST-246 with cyclodextrin, in a pharmaceutically acceptable liquid carrier~~-~~;
~~b) optionally filtering the mixture of step a);~~ and
c) lyophilizing said mixture.

~~40~~20. The process ~~of~~according to claim 19, wherein said cyclodextrin is hydroxypropyl-β-cyclodextrin.

21. A process according to claim 19 or 20 comprising step b) filtering a mixture of step a).